Procter & Gamble agreed to acquire supplement maker Thorne for $3.8 billion, a deal that pushes the consumer giant deeper into the wellness economy. The price signals how seriously household-name players now take the category.
Regulatory review is likely to be straightforward, and integration will be the real test. If P&G lets Thorne keep its voice, the deal could open a new revenue stream; if it folds the brand into the machine, the value may evaporate.
For P&G, the deal adds a premium, science-led brand to a portfolio built on scale and distribution. The question is whether the company’s mass-market machinery can preserve Thorne’s clinical aura.
The supplement category has grown crowded, with startups and legacy players alike chasing the same customer. Thorne’s practitioner channel gives P&G a distribution moat that direct-to-consumer rivals would envy.
The acquisition fits a broader pattern of beauty and personal-care companies absorbing wellness brands to capture spending that migrates between skin care, ingestibles, and overall health routines.
